WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for ...

(RTTNews) - Viridian Therapeutics (VRDN) Monday has granted 113,200 stock options to nine new employees and 310,700 stock options to newly appointed Chief Medical Officer, Dr. Radhika Tripuraneni.

Viridian Therapeutics' VRDN-001 demonstrates rapid efficacy in TED. Read why VRDN stock may benefit from FDA approval and ...

Investment analysts at B. Riley issued their Q1 2025 earnings per share estimates for Viridian Therapeutics in a research ...

provides cash runway into the second half of 2027 - Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in ...

Analysts at Wedbush lifted their Q1 2025 earnings per share estimates for Viridian Therapeutics in a report released on Thursday, February 27th. Wedbush analyst L. Chico now anticipates that the ...

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report), with a price ...

Wedbush analyst Laura Chico maintained a Buy rating on Astria Therapeutics (ATXS – Research Report) today and set a price target of $28.00. The ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases ...

--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare ...